Dark

MRSN
Mersana Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Sep 15, 2025 3:59:30 PM EDT

7.17USD+0.420%(+0.03)30,172

0.00Bid 0.00Ask 0.00Spread

Pre-market

Sep 15, 2025 8:48:30 AM EDT

7.15USD+0.140%(+0.01)100

After-hours

Sep 12, 2025 4:28:30 PM EDT

7.28USD+1.961%(+0.14)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 7, 2022

01:03PM EST Mersana Therapeutics Outlines 2022 Strategic Priorities, Milestones Benzinga

08:00AM EST UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022 GlobeNewswire Inc

Jan 5, 2022

08:20AM EST The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets Benzinga

08:00AM EST Mersana Therapeutics to Present at the 40th Annual J.P. Morgan GlobeNewswire Inc

Jan 4, 2022

05:13AM EST Mersana Therapeutics Director Andrew Hack Reported Purchase of 875,000 Shares @ Avg Price of $5.75/Share in Form 4 Filing on Monday Benzinga

Dec 2, 2021

08:00AM EST Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Boston Globe has named the company among its annual Top Places to Work 2021 list in the midsize employer category. GlobeNewswire Inc

Nov 30, 2021

09:57AM EST 09:57 Tuesday, November 30, 2021Wedbush (RTTNews) - Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $23 Price Target RTTNews

Nov 23, 2021

08:00AM EST Mersana Therapeutics to Participate in the Upcoming 4th Annual GlobeNewswire Inc

Nov 10, 2021

11:51AM EST Mersana Therapeutics's Return On Capital Employed Insights Benzinga

08:00AM EST Mersana Therapeutics to Present at the Upcoming Stifel 2021 GlobeNewswire Inc

Nov 9, 2021

11:56AM EST Mersana Therapeutics S-3 Filing Shows Registration For $300M Mixed Securities Shelf Offering Benzinga

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:26AM EST Mersana Therapeutics Q3 EPS $(0.63) Misses $(0.58) Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

06:13AM EST Mersana Therapeutics Q3 Net Loss $45.5 Mln Or $0.63/Shr Vs Loss Of $22.5 Mln Or $0.33/Shr Last Year RTTNews

06:00AM EST Mersana Therapeutics Announces Third Quarter 2021 Financial GlobeNewswire Inc

Nov 2, 2021

08:00AM EDT Mersana Therapeutics to Host Conference Call Announcing Third GlobeNewswire Inc

Oct 27, 2021

04:05PM EDT Mersana Therapeutics Announces Inducement Grant Under Nasdaq GlobeNewswire Inc

Oct 25, 2021

08:00AM EDT Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., GlobeNewswire Inc

Oct 8, 2021

12:52PM EDT Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings Benzinga

Oct 7, 2021

04:06PM EDT Mersana Therapeutics Announces Target And Presents New Preclinical Data For XMT-2056, First Immunosynthen STING-Agonist ADC, At AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics Benzinga

04:05PM EDT Mersana Therapeutics Announces Target and Presents New Preclinical GlobeNewswire Inc

Sep 30, 2021

08:07AM EDT Mersana Therapeutics To Announce Target And Present New Preclinical Data For XMT-2056 At The AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics Benzinga

08:00AM EDT Mersana Therapeutics to Announce Target and Present New GlobeNewswire Inc

Sep 10, 2021

07:35PM EDT Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views Benzinga

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 7, 2021

08:00AM EDT Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at three upcoming investor conferences. Details are as follows: GlobeNewswire Inc

Sep 5, 2021

01:14PM EDT The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week Benzinga

Sep 1, 2021

08:02AM EDT Mersana Therapeutics Will Host Live Conference Call, Webcast On Friday, Sept. 10, 2021 At 8 a.m. EDT To Discuss Progress Of Its Development Strategy For Upifitamab Rilsodotin, Provide Updated Interim Data From Ovarian Cancer Expansion Cohort Benzinga

08:00AM EDT Mersana Therapeutics to Provide Update on the Progress of its UpRi GlobeNewswire Inc

Aug 30, 2021

06:16AM EDT HC Wainwright & Co. Initiates Coverage On Mersana Therapeutics with Buy Rating, Announces Price Target of $28 Benzinga

Aug 18, 2021

04:05PM EDT Mersana Therapeutics Announces Inducement Grant Under Nasdaq GlobeNewswire Inc

Aug 16, 2021

08:00AM EDT Mersana Therapeutics Announces Appointment of Tushar Misra, Ph.D., GlobeNewswire Inc

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

06:09AM EDT Mersana Therapeutics Q2 EPS $(0.59) Misses $(0.50) Est Benzinga

06:00AM EDT -- Initiated UPGRADE, a Phase 1 platinum combination cohort in platinum-sensitive ovarian cancer -- Company plans to disclose target and preclinical data for XMT-2056, first Immunosynthen STING-agonist ADC, at AACR-NCI-EORTC -- Ended second quarter with $227.4M in cash and equivalents GlobeNewswire Inc

04:22AM EDT Earnings Scheduled For August 6, 2021 Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

08:00AM EDT Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow GlobeNewswire Inc

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 30, 2021

08:00AM EDT Mersana Therapeutics to Host Conference Call Announcing Second GlobeNewswire Inc

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 28, 2021

08:04AM EDT Mersana Therapeutics Announces Initiation Of UPGRADE Phase 1 Platinum Combination Cohort For UpRi In Platinum-Sensitive Ovarian Cancer Benzinga

08:00AM EDT Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 GlobeNewswire Inc

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 29, 2021

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

Jun 24, 2021

09:48AM EDT Return On Capital Employed Overview: Mersana Therapeutics Benzinga

Jun 8, 2021

11:33AM EDT Mersana Therapeutics: Return On Capital Employed Insights Benzinga

May 26, 2021

08:00AM EDT Mersana Therapeutics to Present at Jefferies Virtual Healthcare GlobeNewswire Inc

May 10, 2021

04:11PM EDT Mersana Therapeutics Q1 EPS $(0.50) Misses $(0.39) Estimate, Sales $11.00K, Same YoY Benzinga

04:01PM EDT - Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer- Ended first quarter of 2021 with $228 million in cash GlobeNewswire Inc

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 3, 2021

08:00AM EDT Mersana Therapeutics to Host Conference Call Announcing First GlobeNewswire Inc

Apr 28, 2021

04:05PM EDT Mersana Therapeutics Announces Inducement Grant Under Nasdaq GlobeNewswire Inc

Apr 26, 2021

08:00AM EDT Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer. GlobeNewswire Inc

Apr 16, 2021

09:23AM EDT Mersana Therapeutics Shares Quiet; Co At 8 a.m. ET Began Conference Call, Webcast To Discuss Selection Of NaPi2b Biomarker Cutoff And Commercial Diagnostic Development Path Benzinga

Apr 9, 2021

10:17AM EDT Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients Benzinga

08:15AM EDT Mersana Therapeutics to Host Conference Call and Webcast to GlobeNewswire Inc

08:14AM EDT Mersana Therapeutics Announces Initiation Of Patient Dosing In UPLIFT RTTNews

08:01AM EDT Mersana Therapeutics Reports Initiation Of UPLIFT Single-Arm Registration Strategy For UpRi In Platinum-Resistant Ovarian Cancer Benzinga

08:00AM EDT Mersana Therapeutics Announces Initiation of UPLIFT Single-Arm GlobeNewswire Inc

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

07:17AM EDT Credit Suisse Initiates Coverage On Mersana Therapeutics with Neutral Rating, Announces Price Target of $18 Benzinga

Mar 15, 2021

10:16AM EDT Mersana Therapeutics Announces Publication Of 2 Manuscripts Detailing Preclinical Studies Of Dolaflexin Platform, Upifitamab Rilsodotin (XMT-1536) In AACR Journal Molecular Cancer Therapeutics Benzinga

10:15AM EDT Mersana Therapeutics Announces Publication of Two Manuscripts GlobeNewswire Inc

Mar 11, 2021

08:13AM EST Mersana Therapeutics Appoints Allene Diaz To Board RTTNews

08:00AM EST Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Allene Diaz to its board of directors. GlobeNewswire Inc

Mar 10, 2021

04:39PM EST Mersana Therapeutics To Present 3 Posters At American Association For Cancer Research 2021 On April 10, 2021 Benzinga

04:35PM EST Mersana Therapeutics to Present Three Posters at Upcoming Virtual GlobeNewswire Inc

Feb 26, 2021

06:03AM EST Mersana Therapeutics Q4 EPS $(0.42) Misses $(0.32) Estimate, Sales $10.00K Miss $170.00K Estimate Benzinga

06:00AM EST - UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1 2021 GlobeNewswire Inc

04:52AM EST Earnings Scheduled For February 26, 2021 Benzinga

Feb 19, 2021

08:00AM EST Mersana Therapeutics to Host Conference Call Announcing Fourth GlobeNewswire Inc

Feb 17, 2021

08:00AM EST Mersana Therapeutics to Participate in the SVB Leerink 10th Annual GlobeNewswire Inc

Jan 22, 2021

08:00AM EST Mersana Therapeutics Announces Inducement Grant Under Nasdaq GlobeNewswire Inc

Jan 19, 2021

08:00AM EST Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Carla Poulson has joined the company as Chief Human Resources Officer. GlobeNewswire Inc

Jan 16, 2021

02:22PM EST Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity Benzinga

Jan 13, 2021

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

Jan 6, 2021

08:00AM EST Mersana Therapeutics to Present at the 39th Annual J.P. Morgan GlobeNewswire Inc

Jan 5, 2021

02:33PM EST Mid-Afternoon Market Update: Dow Climbs 250 Points; Boston Private Shares Spike Higher Benzinga

12:21PM EST Mid-Day Market Update: Crude Oil Surges Over 4%; Generation Bio Shares Slide Benzinga

10:27AM EST Mid-Morning Market Update: Markets Edge Higher; ISM Manufacturing PMI Jumps to 60.7 Benzinga

10:02AM EST Mersana Therapeutics Announces Corporate, Pipeline Updates, 2021 Goals And Anticipated Milestones Benzinga

10:00AM EST Mersana Therapeutics Announces Corporate and Pipeline Updates and GlobeNewswire Inc

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

Dec 30, 2020

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 17, 2020

08:00AM EST Mersana Therapeutics to Host Virtual Analyst and Investor Event GlobeNewswire Inc

Dec 3, 2020

09:56AM EST Benzinga's Top Upgrades, Downgrades For December 3, 2020 Benzinga

Dec 2, 2020

04:05PM EST Mersana Therapeutics Announces Inducement Grant Under Nasdaq GlobeNewswire Inc

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 30, 2020

08:11AM EST Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer Benzinga

08:00AM EST Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior GlobeNewswire Inc

Nov 11, 2020

09:06AM EST Mersana Therapeutics Reports Preclinical Data From Immunosynthen STING-Agonist ADC Platform And Pipeline Benzinga

09:00AM EST -- Immunosynthen ADCs activate the STING pathway in both tumor-resident immune cells and in the tumorcells, resulting in robust anti-tumor activity and offering a differentiated approach from other innate immune activators GlobeNewswire Inc

Nov 9, 2020

11:07AM EST SVB Leerink Maintains Outperform on Mersana Therapeutics, Raises Price Target to $28 Benzinga

07:30AM EST Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live webinar on Monday, November 16, 2020 at 8:00 a.m. ET highlighting its novel ImmunosynthenSTING-agonist ADC platform. GlobeNewswire Inc

06:01AM EST Mersana Therapeutics Q3 EPS $(0.33) Misses $(0.30) Estimate, Sales $11.00K Down From $844.00K YoY Benzinga

06:00AM EST -- Presented additional data from XMT-1536 Phase 1 study at ESMO demonstrating compelling and consistent activity and tolerability profile in ovarian cancer -- Received FDA Fast Track Designation for XMT-1536 for patients with heavily-pretreatedovarian cancer -- Ended Q3 2020 with $271 million in cash GlobeNewswire Inc

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 4, 2020

08:00AM EST Mersana Therapeutics to Present at 29th Annual Credit Suisse GlobeNewswire Inc

Nov 2, 2020

08:00AM EST Mersana Therapeutics to Host Conference Call Announcing Third GlobeNewswire Inc

Oct 14, 2020

05:05PM EDT Mersana Therapeutics to Present Preclinical Data from GlobeNewswire Inc

Sep 17, 2020

06:11AM EDT Mersana Therapeutics Reports Updated Interim Data From Ovarian Cancer Cohort Of XMT-1536 Phase 1 Expansion Study RTTNews

06:07AM EDT Mersana Therapeutics Announces The Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study Benzinga

06:00AM EDT - Maintained 34% objective response rate and 79% disease control rate, including two complete responses GlobeNewswire Inc

Sep 15, 2020

10:36AM EDT Shares of Mersana Therapeutics Inc. (MRSN) are losing more than 6 percent or $1.51 in Tuesday's morning trade at $22.66 despite no company-centric news that could influence the stock. RTTNews

Sep 14, 2020

10:11AM EDT Shares of Mersana Therapeutics, Inc. (MRSN) are gaining about 20% Monday morning keeping its last week's momentum. RTTNews

Sep 10, 2020

08:15AM EDT Mersana Therapeutics To Present Updated Interim Data From Ovarian Cancer Cohort Of The XMT-1536 Phase 1 Expansion Study At The 2020 ESMO Virtual Congress Benzinga

08:00AM EDT -Company to Host Conference Call and Webcast Featuring Study Investigator,Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET - GlobeNewswire Inc

Sep 3, 2020

08:00AM EDT Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that management will present at two upcoming investor conferences. Details are as follows: GlobeNewswire Inc

Sep 2, 2020

04:05PM EDT Mersana Therapeutics Announces Inducement Grant Under Nasdaq GlobeNewswire Inc

Aug 31, 2020

08:07AM EDT Mersana Therapeutics Appoints Chuck Miller As SVP Of Regulatory Affairs RTTNews

08:00AM EDT Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Chuck Miller as Senior Vice President of Regulatory Affairs. GlobeNewswire Inc

Aug 11, 2020

01:45PM EDT Mersana Therapeutics shares are trading higher after the company announced it received FDA fast track designation for its XMT-1536, for the treatment of patients with platinum-resistant ovarian cancer. Benzinga

08:19AM EDT Mersana Therapeutics Receives FDA Fast Track Designation For XMT-1536 For Treatment Of Patients With Platinum-Resistant Ovarian Cancer Benzinga

08:00AM EDT Mersana Therapeutics Receives FDA Fast Track Designation for GlobeNewswire Inc

Aug 7, 2020

07:17AM EDT Recap: Mersana Therapeutics Q2 Earnings Benzinga

06:15AM EDT Mersana Therapeutics Q2 EPS $(0.33) Misses $(0.30) Estimate, Sales $796.00K Beat $300.00K Estimate Benzinga

06:00AM EDT - Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate in ovarian cancer GlobeNewswire Inc

04:02AM EDT Earnings Scheduled For August 7, 2020 Benzinga

Aug 6, 2020

04:13PM EDT Earnings Preview for Mersana Therapeutics Benzinga

Aug 4, 2020

08:00AM EDT Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that management will present at two upcoming investor conferences. Details are as follows: GlobeNewswire Inc

Jul 31, 2020

08:00AM EDT Mersana Therapeutics to Host Conference Call Announcing Second GlobeNewswire Inc